Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Biden’s domestic policy adviser says Trump avoided pledges to overhaul the Affordable Care Act and other health programs — but changes are coming anyway.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden leaving 11th-hour health measures for TrumpThe Biden administration in its final days has been

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Advocate highlights social inequality through original stories and opinions, and content generated by fellow NNPA and other publications

the White House announced Wednesday, a 9% jump from the prior year, with a week left for more to enroll. The 2025 enrollment figure is buoyed by 3.2 million new consumers compared to last year, the Center for Medicare & Medicaid Services said, with 20.4 ...

Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

Health policy experts Chris Klomp, Stephanie Carlton and Abe Sutton appear favored for senior roles in the emerging Trump administration.